An Open Label Study Treatment Extension Study of AMG 706
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2016
At a glance
- Drugs Motesanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 12 Jan 2010 Planned end date changed from 1 Feb 2011 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2005-0761).
- 21 Jul 2009 Additional trial locations identified as reported by ClinicalTrials.gov.